Emcure Pharma IPO GMP, Price, Allotment, Profit Estimate 2023

Emcure Pharma IPO Description – Emcure Pharmaceuticals stands as a prominent Indian pharmaceutical entity, dedicated to the advancement, production, and global promotion of an extensive array of pharmaceutical products spanning various critical therapeutic domains. Functioning as a research and development (R&D) oriented enterprise, Emcure boasts a distinct product portfolio encompassing oral medications, injectables, and biotherapeutics. This diverse range has facilitated its market penetration into over 70 countries, establishing a robust presence in India, Europe, and Canada.

Emcure Pharmaceuticals secured notable rankings in the pharmaceutical landscape, clinching the 13th position among the largest pharmaceutical companies in India based on Domestic Sales for MAT September 2023. Additionally, it proudly held the 4th spot in terms of market share in its Covered Markets for the same period. Notably, Emcure emerged as the foremost pharmaceutical company in India for Domestic Sales in the therapeutic areas of gynecology and human immunodeficiency virus (HIV) antivirals for MAT September 2023.

Emcure Pharmaceuticals has 13 manufacturing facilities across India. The company has witnessed substantial sales expansion in India over the recent years. Its sales in India accounted for 50.84% and 53.16% of the total revenue from operations during the six months ended 30 September 2023, and the entire FY 2023, respectively.

The competitive edge of the company in the domestic market arises from its distinctive product portfolio. This uniqueness has enabled the company to establish a strong presence in numerous critical therapeutic areas, encompassing gynecology, cardiovascular health, vitamins, minerals, nutrients, HIV antivirals, blood-related disorders, and oncology/anti-neoplastic. Across all such therapeutic areas, it is ranked among the top 10 pharmaceutical companies in India in terms of domestic sales in India in September 2023.

Promoters of Emcure Pharma – Satish Ramanlal Mehta, and Sunil Rajanikant Mehta

Emcure Pharma IPO Details

Emcure Pharma IPO Dates	Coming soon
Emcure Pharma Issue Price	Coming soon
Fresh issue	INR 800 crore
Offer For Sale	13,678,839 shares
Total IPO size	Coming soon
Minimum bid (lot size)	Coming soon
Face Value	INR 10 per share
Retail Allocation	35%
Listing On	BSE, NSE

Emcure Pharma’s Financial Performance

	FY 2021	FY 2022	FY 2023	H1 FY 2024
Revenue	5,033.47	5,855.39	5,985.81	3,219.25
Expenses	4,222.13	4,946.31	5,278.36	2,843.06
Net income	418.59	702.56	561.85	286.80
Margin (%)	8.32	12.00	9.39	8.91

Figures in INR Crores unless specified otherwise

Emcure Pharma IPO News

Emcure Pharma Valuations & Margins

	FY 2021	FY 2022	FY 2023
EPS	21.68	36.62	29.42
PE ratio	–	–	–
RONW (%)	17.25	33.32	21.27
NAV	125.68	109.90	138.30
ROCE (%)	20.58	29.69	22.01
EBITDA (%)	19.35	23.54	20.24
Debt/Equity	–	–	–

Emcure Pharma IPO GMP Today (Daily Trend)

Emcure Pharma IPO Objectives

Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company
General corporate purposes

Emcure Pharma IPO Subscription – Live Updates

Coming soon

Emcure Pharma – Comparison With Listed Peers

Company	PE ratio	EPS	RONW (%)	NAV	Revenue (Cr.)
Emcure Pharmaceuticals	–	29.42	21.27	138.30	5,985.81
Dr. Reddy’s Laboratories	20.45	270.90	19.36	1,398.33	24,669.70
Cipla Limited	34.55	34.69	11.97	290.01	22,753.12
Alkem Laboratories	58.25	82.31	10.88	756.52	11,599.26
Torrent Pharmaceuticals	55.66	36.79	20.09	183.13	9,620.15
Mankind Pharma	57.80	32.00	17.24	185.61	8,749.43
Abbott India	51.10	446.78	29.78	1,500.54	5,348.73
J. B. Chemicals & Pharmaceuticals	55.72	26.17	16.52	320.55	3,149.28

Emcure Pharma IPO Allotment Status

Emcure Pharma IPO allotment will be available on Link Intime’s website. Click on this link to get allotment status.

Emcure Pharma IPO Dates & Listing Performance

Emcure Pharma IPO Opening Date	Coming soon
Emcure Pharma IPO Closing Date	Coming soon
Finalisation of Basis of Allotment	Coming soon
Initiation of refunds	Coming soon
Transfer of shares to demat accounts	Coming soon
Emcure Pharma IPO Listing Date	Coming soon
Opening Price on NSE	Coming soon
Closing Price on NSE	Coming soon

Angel One –
Anand Rathi –
Axis Capital –
Antique Stock Broking –
Arihant Capital –
Ashika Research –
Asit C Mehta –
BP Wealth –
Capital Market –
Canara Bank Securities –
Choice Broking –
Dalal & Broacha –
Elite Wealth –
GCL Broking –
Geojit –
GEPL Capital –
Hem Securities –
ICICIdirect –
Investmentz –
Jainam Broking –
DR Choksey –
LKP Research –
Marwadi Financial –
Motilal Oswal –
Nirmal Bang –
Reliance Securities –
Religare Broking –
Samco Securities –
SMC Global –
Swastika Investmart –
Ventura Securities –

Emcure Pharma Offer Lead Manager

KOTAK MAHINDRA CAPITAL COMPANY LIMITED
27 BKC, 1st Floor, Plot no. C-27,
‘G’ Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051
Phone: +91 22 4336 0000
Email: [email protected]
Website: www.investmentbank.kotak.com

Emcure Pharma Offer Registrar

Link Intime India Private Limited
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West), Mumbai 400 083, Maharashtra, India
Phone: +91 810 811 4949
Email: [email protected]
Website: www.linkintime.co.in

EMCURE PHARMACEUTICALS LIMITED
Plot No. P-1 and P-2, IT-BT Park, Phase II,
M.I.D.C., Hinjawadi, Pune 411 057, Maharashtra
Phone: +91 20 3507 0033, +91 20 3507 0000
Email: [email protected]
Website: www.emcure.com

Emcure Pharma IPO FAQs

How many shares in Emcure Pharma IPO are reserved for HNIs and retail investors?

The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.

How to apply in Emcure Public Offer?

The best way to apply in Emcure public offer is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stock broker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.